Compare ABEO & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABEO | USNA |
|---|---|---|
| Founded | 1974 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 342.7M |
| IPO Year | 2005 | 1996 |
| Metric | ABEO | USNA |
|---|---|---|
| Price | $5.80 | $18.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 101.8K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | $2,998,000.00 | ★ $1,060,902,000.00 |
| Revenue This Year | $1,024.31 | $3.90 |
| Revenue Next Year | $145.42 | $6.21 |
| P/E Ratio | ★ N/A | $46.09 |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $16.60 |
| 52 Week High | $7.54 | $38.32 |
| Indicator | ABEO | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 48.12 |
| Support Level | $5.20 | $16.77 |
| Resistance Level | $6.07 | $21.16 |
| Average True Range (ATR) | 0.25 | 0.84 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 75.40 | 53.98 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).